Literature DB >> 22003062

Sarcomatoid renal cell carcinoma is an example of epithelial--mesenchymal transition.

Joanna L Conant1, Zhihua Peng, Mark F Evans, Shelly Naud, Kumarasen Cooper.   

Abstract

BACKGROUND: Sarcomatoid renal cell carcinomas (SRCC) are composed of two cell populations, a sarcomatous component (SC) and a carcinomatous component (CC). SRCC are particularly aggressive and often present at an advanced stage at diagnosis. Epithelial-mesenchymal transition (EMT) has been proposed as a mechanism for the development of SC from CC. AIMS AND METHODS: E- to N-cadherin switching, localisation of β-catenin, and expression of Snail and secreted protein acidic and rich in cysteine (SPARC) (markers of EMT) were studied to determine whether SRCC is an example of EMT. Expression of these markers was analysed by immunohistochemistry on 21 cases of SRCC that had both SC and CC and scored according to intensity and extent.
RESULTS: E-cadherin expression was decreased in SC (Wilcoxon signed-rank test, p=0.0004) while N-cadherin expression was high in both components (p=0.46). Membranous β-catenin expression was decreased in SC (p<0.0001) while cytoplasmic expression was increased (p=0.0002). Snail and SPARC had higher expression in SC (p=0.002 and p<0.0001, respectively). When the scores were dichotomised into low and high expression levels, the results using McNemar's test substantiated the above results.
CONCLUSIONS: E- to N-cadherin switching, dissociation of β-catenin from the membrane, and increased expression of Snail and SPARC in SC indicate that SRCC is an example of EMT. High expression of N-cadherin and Snail in CC suggest early involvement in initiating EMT. Once EMT is established, loss of E-cadherin, release of β-catenin into the cytoplasm, and expression of SPARC correspond with mesenchymal phenotypic expression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22003062     DOI: 10.1136/jclinpath-2011-200216

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  31 in total

1.  Activation of hepatocyte growth factor/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate.

Authors:  Jiaqi Mi; Erika Hooker; Steven Balog; Hong Zeng; Daniel T Johnson; Yongfeng He; Eun-Jeong Yu; Huiqing Wu; Vien Le; Dong-Hoon Lee; Joseph Aldahl; Mark L Gonzalgo; Zijie Sun
Journal:  J Biol Chem       Date:  2018-11-06       Impact factor: 5.157

2.  Biophysical changes caused by altered MUC13 expression in pancreatic cancer cells.

Authors:  Andrew E Massey; Kyle A Doxtater; Murali M Yallapu; Subhash C Chauhan
Journal:  Micron       Date:  2020-01-03       Impact factor: 2.251

3.  Lack of TMEM27 expression is associated with postoperative progression of clinically localized conventional renal cell carcinoma.

Authors:  Andras Javorhazy; Nelli Farkas; Tamas Beothe; Csaba Pusztai; Arpad Szanto; Gyula Kovacs
Journal:  J Cancer Res Clin Oncol       Date:  2016-07-14       Impact factor: 4.553

4.  Sarcomatoid renal cell carcinoma: genomic insights from sequencing of matched sarcomatous and carcinomatous components.

Authors:  Brandon J Manley; James J Hsieh
Journal:  Transl Cancer Res       Date:  2016-08       Impact factor: 1.241

5.  Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: a retrospective analysis.

Authors:  Sumanta K Pal; Jeremy O Jones; Courtney Carmichael; Junmi Saikia; Joanne Hsu; Xueli Liu; Robert A Figlin; Przemyslaw Twardowski; Clayton Lau
Journal:  Urol Oncol       Date:  2012-05-17       Impact factor: 3.498

6.  RNA-seq reveals aurora kinase-driven mTOR pathway activation in patients with sarcomatoid metastatic renal cell carcinoma.

Authors:  Sumanta K Pal; Miaoling He; Tommy Tong; Huiqing Wu; Xueli Liu; Clayton Lau; Jin-Hui Wang; Charles Warden; Xiwei Wu; Sabina Signoretti; Toni K Choueiri; Jose A Karam; Jeremy O Jones
Journal:  Mol Cancer Res       Date:  2014-09-02       Impact factor: 5.852

7.  Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma.

Authors:  Mark Bi; Siming Zhao; Jonathan W Said; Maria J Merino; Adebowale J Adeniran; Zuoquan Xie; Cayce B Nawaf; Jaehyuk Choi; Arie S Belldegrun; Allan J Pantuck; Harriet M Kluger; Kaya Bilgüvar; Richard P Lifton; Brian Shuch
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-10       Impact factor: 11.205

8.  Grade 4 unclassified renal cell carcinoma with sarcomatoid component expressing S-100 protein. A case report with peculiar diagnostic and therapeutic implications.

Authors:  Gianmaria Miolo; Anthony Ash; Angela Buonadonna; Giovanni Lo Re; Elena Torrisi; Silvia Cervo; Davide Adriano Santeufemia; Alessandro Tuzi; Vincenzo Canzonieri
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

9.  Does postoperative radiation therapy impact survival in non-metastatic sarcomatoid renal cell carcinoma? A SEER-based study.

Authors:  Okyaz Eminaga; Ilgar Akbarov; Sebastian Wille; Udo Engelmann
Journal:  Int Urol Nephrol       Date:  2015-09-02       Impact factor: 2.370

Review 10.  Epithelial to Mesenchymal Transition in Renal Cell Carcinoma: Implications for Cancer Therapy.

Authors:  Francesco Piva; Matteo Giulietti; Matteo Santoni; Giulia Occhipinti; Marina Scarpelli; Antonio Lopez-Beltran; Liang Cheng; Giovanni Principato; Rodolfo Montironi
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.